¿¬¼ö°­ÁÂ
2024 ºñ´¢±âÃÊÀÇÇבּ¸È¸ ¿ä·Î»ý½Ä±â ¼Õ»óÀç°Ç¿¬±¸È¸ °øµ¿ Çмú´ëȸ : 2024-02-24

2024 ºñ´¢±âÃÊÀÇÇבּ¸È¸ ¿ä·Î»ý½Ä±â ¼Õ»óÀç°Ç¿¬±¸È¸ °øµ¿ Çмú´ëȸ : 2024-02-24
±³À°ÀÏÀÚ : 2024-02-24
±³À°Àå¼Ò : ¼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ3Ãþ ¼­¾Ï°­´ç

±³À°ÁÖÁ¦ : 2024 ºñ´¢±âÃÊÀÇÇבּ¸È¸ ¿ä·Î»ý½Ä±â ¼Õ»óÀç°Ç¿¬±¸È¸ °øµ¿ Çмú´ëȸ

ÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºñ´¢±â°è±âÃÊÀÇÇבּ¸È¸

´ã´çÀÚ : À̼¼Èñ
¿¬¶ôó : 02-573-8190

À̸ÞÀÏ : urology@urology.or.kr

±³À°Á¾·ù : ºñ´¢ÀÇÇаú

Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 40ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 08:20~08:50 Registration ( )

±âŸ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 08:50~08:55 Welcome & Introduction ( )

±âŸ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 08:55~09:00 KUA President¡¯s Welcome ( )

±³À°½Ã°£ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 09:00~09:30 AI ¾Ù°í¸®µëÀ» ÀÌ¿ëÇÑ ¾Ï¹é½Å °³¹ß Á¶À±¼º(ÀιÙÀÌÃ÷Áö³ë¹Í½º)

±³À°½Ã°£ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 09:30~10:00 Male genitourethral and perineal anatomy and principles of urethroplasty: video-based lecture ¼ºÇöȯ(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 10:00~10:30 Current trend in ADC development À¯ÅÂÇö(¾ÆÁÖ´ë ºÐÀÚ°úÇбâ¼úÇаú)

±³À°½Ã°£ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 10:30~11:00 Update on the clinical utility of ADC ±èÀÎÈ£(°¡Å縯ÀÇ´ë)

ÈÞ½Ä 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 11:00~11:20 Break ( )

±³À°½Ã°£ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 11:20~11:40 Catheterization-associated urethral injury (CAUI) À¯¼ºÇö(Àü³²ÀÇ´ë)

±³À°½Ã°£ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 11:40~12:00 Iatrogenic injury of the lower urinary tract from BPH surgery ¹Ú¹Î±¸(°í·ÁÀÇ´ë)

±³À°½Ã°£ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 12:00~12:20 Immune checkpoint molecule-targeting recombinant dendritic cells for therapeutic effect on prostate cancer ÃÖÁß¿ø(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 12:20~12:40 A 23-gene prognostic index predicts progression and BCG response in non-muscle invasive bladder cancer À±¼®Áß(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 02¿ù 24ÀÏ ½ÅÃ̼¼ºê¶õ½º ¾Ïº´¿ø ÁöÇÏ 3Ãþ ¼­¾Ï°­´ç 12:40~13:00 Prostate cancer docetaxel and androgen targeting agent response prediction by transcriptome analysis ÇÑÇöÈ£(¿¬¼¼ÀÇ´ë)

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ÀÏ¿ø¿ª»ç Bµ¿ 9Ãþ È÷Æ÷Å©¶óÅ×½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇѳúÁ¹ÁßÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/

Ãßõ¼ö : 0 , Á¶È¸¼ö : 7,085 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­Á : 2024-03-09

±³À°ÀÏÀÚ : 2024-03-09 ±³À°Àå¼Ò : (¿Â¶óÀÎ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ½Å¼ººóÇ÷¿¬

Ãßõ¼ö : 0 , Á¶È¸¼ö : 7,055 , ´ñ±Û¼ö : 0

[¼­¿ï] Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialysis Vascular Access) : 2024-03-31

±³À°ÀÏÀÚ : 2024-03-31 ±³À°Àå¼Ò : °¡Å縯ÀÇ´ë ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ ±³À°ÁÖÁ¦ : Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialy

Ãßõ¼ö : 0 , Á¶È¸¼ö : 7,097 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­Á : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ¿Â¶óÀÎ »ýÁß°è ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ ´ã´çÀÚ : °û¼ÖÀÌ ¿¬¶ôó : 02-71

Ãßõ¼ö : 0 , Á¶È¸¼ö : 7,184 , ´ñ±Û¼ö : 0

[¼­¿ï] ´ëÇÑÁ¶Çöº´ÇÐȸ Treatment and management of symptoms and physical health in schizophrenia : 2024-04-2..

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ±³À°ÁÖÁ¦ : Treatment and management of symptoms and physical health i

Ãßõ¼ö : 0 , Á¶È¸¼ö : 6,786 , ´ñ±Û¼ö : 0